A theoretical quantitative model for evolution of cancer chemotherapy resistance

Biology Direct

Volumn 5, Issue , 2010, Pages

  Silva, Ariosto S ^a   Gatenby, Robert A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYGLUCOSE;

ANIMAL; ARTICLE; DRUG RESISTANCE; HUMAN; MAXIMUM TOLERATED DOSE; NEOPLASM; THEORETICAL MODEL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYGLUCOSE; DRUG RESISTANCE, NEOPLASM; HUMANS; MAXIMUM TOLERATED DOSE; MODELS, THEORETICAL; NEOPLASMS;

EID: 77950925366     PISSN: None     EISSN: 17456150     Source Type: Journal    
DOI: 10.1186/1745-6150-5-25     Document Type: Article

References (40)

1. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984, 44:3643-3653.
2. Galmarini CM, Galmarini FC. Multidrug resistance in cancer therapy: role of the microenvironment. Curr Opin Investig Drugs 2003, 4:1416-1421.
3. Goldie JH. Drug resistance in cancer: a perspective. Cancer Metastasis Rev 2001, 20:63-68. 10.1023/A:1013164609041, 11831649.
4. Greijer AE, de Jong MC, Scheffer GL, Shvarts A, van Diest PJ, Wall E. Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol 2005, 27:43-49.
5. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001, 3:323-327. 10.1186/bcr315, 138696, 11597322.
6. Tomida A, Tsuruo T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 1999, 14:169-177.
7. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14:2519-2526. 10.1158/1078-0432.CCR-07-2223, 18451212.
8. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ, Dalton WS. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993, 81:490-495.
9. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 1986, 46:5125-5130.
10. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 1991, 51:995-1002.
11. Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW, De Jong MC, Dalton WS. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res 1999, 59:1021-1028.
12. Tannock I, Hill RP, Bristow RG, Harrington L. The Basic Science of Oncology. 2005, McGraw-Hill Professional.
13. Lankelma J, Dekker H, Luque FR, Luykx S, Hoekman K, Valk P, van Diest PJ, Pinedo HM. Doxorubicin gradients in human breast cancer. Clin Cancer Res 1999, 5:1703-1707.
14. Lankelma J, Fernandez Luque R, Dekker H, Schinkel W, Pinedo HM. A mathematical model of drug transport in human breast cancer. Microvasc Res 2000, 59:149-161. 10.1006/mvre.1999.2218, 10625582.
15. Gautam A, Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 2006, 66:6497-6502. 10.1158/0008-5472.CAN-05-4462, 16818620.
16. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004, 64:3761-3766. 10.1158/0008-5472.CAN-03-3363, 15172981.
17. Gatenby RA. A change of strategy in the war on cancer. Nature 2009, 459:508-509. 10.1038/459508a, 19478766.
18. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res 2009, 69:4894-4903. 10.1158/0008-5472.CAN-08-3658, 19487300.
19. Sridhar R, Stroude EC, Inch WR. Cytotoxicity of glucose analogues in V79 multicell spheroids. In Vitro 1979, 15:685-690. 10.1007/BF02618247, 535913.
20. Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 2001, 40:5542-5547. 10.1021/bi002426w, 11331019.
21. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008, 49(Suppl 2):24S-42S. 10.2967/jnumed.107.047258, 18523064.
22. Gregory WM, Richards MA, Slevin ML, Souhami RL. A mathematical model relating response durations to amount of subclinical resistant disease. Cancer Res 1991, 51:1210-1216.
23. Silva AS, Yunes JA, Gillies RJ, Gatenby RA. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res 2009, 69:2677-2684. 10.1158/0008-5472.CAN-08-2394, 19276380.
24. Patel AA, Gawlinski ET, Lemieux SK, Gatenby RA. A cellular automaton model of early tumor growth and invasion. J Theor Biol 2001, 213:315-331. 10.1006/jtbi.2001.2385, 11735284.
25. Nichols MG, Foster TH. Oxygen diffusion and reaction kinetics in the photodynamic therapy of multicell tumour spheroids. Phys Med Biol 1994, 39:2161-2181. 10.1088/0031-9155/39/12/003, 15551546.
26. Groebe K, Erz S, Mueller-Klieser W. Glucose diffusion coefficients determined from concentration profiles in EMT6 tumor spheroids incubated in radioactively labeled L-glucose. Adv Exp Med Biol 1994, 361:619-625.
27. Casciari JJ, Sotirchos SV, Sutherland RM. Variations in tumor cell growth rates and metabolism with oxygen concentration, glucose concentration, and extracellular pH. J Cell Physiol 1992, 151:386-394. 10.1002/jcp.1041510220, 1572910.
28. Smallbone K, Gatenby RA, Gillies RJ, Maini PK, Gavaghan DJ. Metabolic changes during carcinogenesis: potential impact on invasiveness. J Theor Biol 2007, 244:703-713. 10.1016/j.jtbi.2006.09.010, 17055536.
29. Anderson AR. A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion. Math Med Biol 2005, 22:163-186. 10.1093/imammb/dqi005, 15781426.
30. Laginha KM, Verwoert S, Charrois GJ, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 2005, 11:6944-6949. 10.1158/1078-0432.CCR-05-0343, 16203786.
31. Ferreira SC, Martins ML, Vilela MJ. Morphology transitions induced by chemotherapy in carcinomas in situ. Phys Rev E Stat Nonlin Soft Matter Phys 2003, 67:051914.
32. Ceccarini C, Eagle H. pH as a determinant of cellular growth and contact inhibition. Proc Natl Acad Sci USA 1971, 68:229-233. 10.1073/pnas.68.1.229, 391201, 4322262.
33. Williams AC, Collard TJ, Paraskeva C. An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene 1999, 18:3199-3204. 10.1038/sj.onc.1202660, 10359525.
34. Park HJ, Lyons JC, Ohtsubo T, Song CW. Acidic environment causes apoptosis by increasing caspase activity. Br J Cancer 1999, 80:1892-1897. 10.1038/sj.bjc.6690617, 2363148, 10471036.
35. Roth GS, Ingram DK, Lane MA. Caloric restriction in primates and relevance to humans. Ann N Y Acad Sci 2001, 928:305-315.
36. Tagg SL, Foster PA, Leese MP, Potter BV, Reed MJ, Purohit A, Newman SP. 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer. Br J Cancer 2008, 99:1842-1848. 10.1038/sj.bjc.6604752, 2600694, 18985042.
37. Frieboes HB, Edgerton ME, Fruehauf JP, Rose FR, Worrall LK, Gatenby RA, Ferrari M, Cristini V. Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res 2009, 69:4484-4492. 10.1158/0008-5472.CAN-08-3740, 19366802.
38. Kitano H. Cancer robustness: tumour tactics. Nature 2003, 426:125. 10.1038/426125a, 14614483.
39. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res 2009, 69:4894-903. 10.1158/0008-5472.CAN-08-3658, 19487300.
40. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009, 114(27):5436-43. 10.1182/blood-2009-07-204651, 19861683.